RESUMEN
The efficacy of naftidrofuryl ( Dusodril ) for treatment of stage II arterial occlusive disease was evaluated in a controlled multi-centre study in a total of 104 out-patients with angiographically documented localization of occlusion. The therapeutic effect was assessed over three months by measurements of walking distance using standardized treadmill conditions. Further parameters were venoocclusive plethysmography and Doppler ultrasonography measurement of pressures. The complaint-free walking distance increased significantly during daily application of 600 mg naftidrofuryl orally (n = 54) during the 12-week assessment period when compared to the placebo group (n = 50). Taking the intraindividual variability of 17.2 m in assessment of walking distance into account, the increase of painless walking of 93 m after treatment for 12 weeks in the active-drug group is considered the result of treatment-induced increased performance.
Asunto(s)
Arteriopatías Oclusivas/tratamiento farmacológico , Arteria Femoral , Furanos/administración & dosificación , Nafronil/administración & dosificación , Administración Oral , Adulto , Anciano , Ensayos Clínicos como Asunto , Método Doble Ciego , Femenino , Marcha , Humanos , Claudicación Intermitente/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Distribución Aleatoria , Factores de TiempoRESUMEN
Etofibrate retard administered in a daily dose 500 mg to 14 outpatients with hyperlipoproteinemia type IIa decreased the cholesterol only 1.7% after a treatment period of 6 weeks. After a treatment of 12 weeks the serum cholesterol was higher in 10 of the 14 patients than in the pretreatment period. Of low grade was the effect of etofibrate retard in 6 patients with type IIb or IV. The triglycerides decreased from 564 mg/dl to 455 mg/dl in the mean. The effect of this double ester from clofibrinic and nicotinic acid (59% to 41%) is uncertain in HLP type IIa, IIb and IV in the recommended dose of 500 mg/day.
Asunto(s)
Clofibrato/uso terapéutico , Hipercolesterolemia/tratamiento farmacológico , Hiperlipidemias/tratamiento farmacológico , Ácidos Nicotínicos/uso terapéutico , Anciano , Colesterol/sangre , Femenino , Humanos , Hipercolesterolemia/sangre , Hiperlipidemias/sangre , Masculino , Persona de Mediana Edad , Triglicéridos/sangreRESUMEN
In 50 patients, both outpatients and inpatients, electrocardiograms were recorded in different phases during esophagogastroscopy. The changes which occurred, such as tachycardia, arrhythmias, and disorders of repolarization are discussed. The increased frequency during the initial stage of the endoscopy, which may assume an already dangerous dimension for patients with coronary heart disease, merits particular attention.